U.S. Markets closed

The Halozyme Therapeutics (NASDAQ:HALO) Share Price Has Gained 99% And Shareholders Are Hoping For More

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, Halozyme Therapeutics, Inc. (NASDAQ:HALO) shareholders have seen the share price rise 99% over three years, well in excess of the market return (42%, not including dividends). On the other hand, the returns haven't been quite so good recently, with shareholders up just 3.5%.

View our latest analysis for Halozyme Therapeutics

Given that Halozyme Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last 3 years Halozyme Therapeutics saw its revenue grow at 18% per year. That's pretty nice growth. While the share price has done well, compounding at 26% yearly, over three years, that move doesn't seem over the top. Of course, valuation is quite sensitive to the rate of growth. Of course, it's always worth considering funding risks when a company isn't profitable.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:HALO Income Statement, July 4th 2019

Take a more thorough look at Halozyme Therapeutics's financial health with this free report on its balance sheet.

A Different Perspective

Halozyme Therapeutics shareholders gained a total return of 3.5% during the year. But that return falls short of the market. It's probably a good sign that the company has an even better long term track record, having provided shareholders with an annual TSR of 13% over five years. It's quite possible the business continues to execute with prowess, even as the share price gains are slowing. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

We will like Halozyme Therapeutics better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.